Literature DB >> 9456213

Treatment choices by seriously ill patients: the Health Stock Risk Adjustment model.

D J Gaskin1, J Kong, N J Meropol, K R Yabroff, C Weaver, K A Schulman.   

Abstract

Anecdotal evidence suggests that patients who have life-threatening conditions often choose to undergo high-cost, high-risk treatments for them. This kind of risk-seeking behavior seems irrational because most patients are risk-averse. The Health Stock Risk Adjustment (HSRA) model seeks to explain this phenomenon. The model is based on the concept of relative health stock--the ratio of patients' expected quality-adjusted life years (QALYs) after a diagnosis to their expected QALYs before the diagnosis. The model predicts risk-averse patients will behave in a risk-seeking manner as their relative health stocks deteriorate. The HSRA model can help physicians better understand why some seriously ill patients seek high-risk treatments while others elect to forgo treatment. State legislatures and insurers are attempting to appropriately design insurance benefits for patients with life-threatening conditions. The HSRA model can help predict which patients will most likely take advantage of these benefits.

Entities:  

Mesh:

Year:  1998        PMID: 9456213     DOI: 10.1177/0272989X9801800116

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  7 in total

Review 1.  Decision making and quality of life in the treatment of cancer: a review.

Authors:  S Yousuf Zafar; Stewart C Alexander; Kevin P Weinfurt; Kevin A Schulman; Amy P Abernethy
Journal:  Support Care Cancer       Date:  2008-09-19       Impact factor: 3.603

2.  Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.

Authors:  Mahdi Gharaibeh; Ali McBride; David S Alberts; Brian Erstad; Marion Slack; Nimer Alsaid; J Lyle Bootman; Ivo Abraham
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

3.  A Web-based communication aid for patients with cancer: the CONNECT Study.

Authors:  Neal J Meropol; Brian L Egleston; Joanne S Buzaglo; Andrew Balshem; Al B Benson; Donald J Cegala; Roger B Cohen; Michael Collins; Michael A Diefenbach; Suzanne M Miller; Linda Fleisher; Jennifer L Millard; Eric A Ross; Kevin A Schulman; Allison Silver; Elyse Slater; Nicholas Solarino; Daniel P Sulmasy; Jonathan Trinastic; Kevin P Weinfurt
Journal:  Cancer       Date:  2013-01-18       Impact factor: 6.860

4.  An Internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study.

Authors:  Joanne S Buzaglo; Jennifer L Millard; Caroline G Ridgway; Eric A Ross; Susan P Antaramian; Suzanne M Miller; Neal J Meropol
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

5.  Cost implications of new treatments for advanced colorectal cancer.

Authors:  Yu-Ning Wong; Neal J Meropol; William Speier; Daniel Sargent; Richard M Goldberg; J Robert Beck
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

6.  Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives.

Authors:  J W Kim; S-J Kim; Y-H Chung; J-H Kwon; H-J Lee; Y-J Chung; Y J Kim; Do-Youn Oh; S-H Lee; D-W Kim; S-A Im; T-Y Kim; D S Heo; Y-J Bang
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

7.  "Nudge" in the clinical consultation--an acceptable form of medical paternalism?

Authors:  Ajay Aggarwal; Joanna Davies; Richard Sullivan
Journal:  BMC Med Ethics       Date:  2014-04-17       Impact factor: 2.652

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.